1-3 of 3
Luca Frison, MD
Close
Sort by
Journal Articles

Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study

Mario Tiribelli, MD, Massimiliano Bonifacio, Gianni Binotto, MD, Alessandra Iurlo, MD, Francesca Cibien, MD, Elena Maino, MD, Anna Guella, MD, Gianluca Festini, MD, Claudia Minotto, MD, Ercole De Biasi, MD, Federico De Marchi, MD, Luigi Scaffidi, Luca Frison, MD, Cristina Bucelli, MD, Marta Medeot, MD, Elisabetta Calistri, MD, Mauro Krampera, Filippo Gherlinzoni, MD, Gianpietro Semenzato, Achille Ambrosetti, MD, Giovanni Pizzolo, Renato Fanin
Journal: Blood
Blood (2016) 128 (22): 5434.
https://doi.org/10.1182/blood.V128.22.5434.5434
Published: 2016
Journal Articles

Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors

Gianni Binotto, MD, Luca Frison, MD, Elisa Boscaro, PhD, Renato Zambello, MD, Federica Lessi, MD, Anna Parolo, MD, Francesco Piazza, MD, Roberta Bertorelle, PhD, Laura Bonaldi, MD, Gianpietro Semenzato, MD
Journal: Blood
Blood (2014) 124 (21): 5508.
https://doi.org/10.1182/blood.V124.21.5508.5508
Published: 2014
Journal Articles

Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The “Gruppo Triveneto LMC”

Massimiliano Bonifacio, MD, Gianni Binotto, MD, Mario Tiribelli, MD, Elisabetta Calistri, MD, Elena Maino, MD, Roberta Zanotti, MD, Luca Frison, MD, Luciana Marin, MD, Renato Fanin, MD, Gianpietro Semenzato, MD, Giovanni Pizzolo, MD
Journal: Blood
Blood (2013) 122 (21): 2732.
https://doi.org/10.1182/blood.V122.21.2732.2732
Published: 2013